| Project/Area Number |
10558113
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 展開研究 |
|---|
| Research Field |
Neurochemistry/Neuropharmacology
|
|---|
| Research Institution | Hiroshima University |
|---|
Principal Investigator |
OHTA Shigeru Hiroshima University, Faculty of Medicine, Professor, 医学部, 教授 (60160503)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KITAMURA Shigeyuki Hiroshima University, Faculty of Medicine, Associate Professor, 医学部, 助教授 (40136057)
YOSHIHARA Shinichi Hiroshima University, Faculty of Medicine, Associate Professor, 医学部, 助教授 (00037607)
NAKAMURA Shigenobu Hiroshima University, Faculty of Medicine, Professor, 医学部, 教授 (30026843)
SUGIHARA Kazumi Hiroshima University, Faculty of Medicine, Research Associate, 医学部, 教務員 (20271067)
|
|---|
| Project Period (FY) |
1998 – 1999
|
| Project Status |
Completed (Fiscal Year 1999)
|
| Budget Amount *help |
¥11,600,000 (Direct Cost: ¥11,600,000)
Fiscal Year 1999: ¥1,600,000 (Direct Cost: ¥1,600,000)
Fiscal Year 1998: ¥10,000,000 (Direct Cost: ¥10,000,000)
|
|---|
| Keywords | tetrahydroisoquinoline / Parkinson's disease / early marker / aldehydeoxidase / Parkinson's disease causing substance / アルデヒドオキシダーゼ |
|---|
| Research Abstract |
The significant decrease in 1MeTIQ content in the brain of PD patients may be due to an increase in the rate of degradation of 1MeTIQ and/or a decrease of 1MeTIQ biosynthesis. Our results support the idea that endogenous and exogenous inducers of parkinsonism do inhibit the biosynthesis of 1MeTIQ, which bas a parkinsonism-preventive effect via an unknown mechanism. Our findings are also consistent with a report that the 1MeTIQ content is decreased in MPTP-treated C57BL/6 mouse brain. Deprenyl can reduce the content of 1BnTIQ (a parkinsonism-including compound) and increase the content of 1MeTIQ (a parkinsonism-protective compound). The balance of 1BnTIQ content to 1MeTIQ content may be very important especially striatum and substantia nigra of PD patients. Development of the anti-parkinsonian drug for above mentioned mechanism is desirable.
|
